Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hand Dermatoses Clear all
Completed Phase 1Phase 2 Interventional Results available

Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet

NCT00585650
View directory record Official record
Conditions
Psoriasis
Interventions
Etanercept, Placebo injections
Biological · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Irvine, California • Winston-Salem, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced Jul 22, 2026, 12:34 PM EDT
Terminated Not applicable Interventional

Vitamin B6 Can Prevent Hand and Foot Syndrome in Cancer Patients Capecitabine Chemotherapy

NCT00767689
View directory record Official record
Conditions
Hand and Foot Syndrome
Interventions
Vitamin B 6, placebo
Drug
Lead sponsor
Cook County Health
Government
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jul 22, 2026, 12:34 PM EDT
Terminated No phase listed Observational

Effect of Body Position and Probe Position on the Localization of Breast Mass

NCT02997540
View directory record Official record
Conditions
Breast Diseases
Interventions
Not listed
Lead sponsor
MetriTrack, Inc.
Industry
Eligibility
21 Years to 70 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Jul 22, 2026, 12:34 PM EDT
Completed Not applicable Interventional Results available

Treatment of Staphylococcus Aureus Colonization in Hand Eczema

NCT01591785
View directory record Official record
Conditions
Hand Eczema, Foot Eczema
Interventions
Retapamulin 1% ointment, Placebo
Drug
Lead sponsor
Gary Goldenberg
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Jul 22, 2026, 12:34 PM EDT
Terminated Phase 2 Interventional Results available

Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer

NCT00751101
View directory record Official record
Conditions
Breast Cancer, Chemotherapeutic Agent Toxicity, Palmar-plantar Erythrodysesthesia
Interventions
Nicotine patch
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Jul 22, 2026, 12:34 PM EDT
Terminated Phase 2 Interventional Results available

Sorafenib-induced Hand- Foot Skin Reaction Treatment

NCT00667589
View directory record Official record
Conditions
Hand-foot Skin Reaction, Rash
Interventions
urea 40% cream, fluocinonide 0.05% cream, tazarotene 0.1% cream, bland emollient cream (Udderly smooth® Udder Cream)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Jul 22, 2026, 12:34 PM EDT
Not listed Not applicable Interventional

Novel Splinting Technique Using 3D Models

NCT05351060
View directory record Official record
Conditions
Arthritis, Osteoarthritis Hand, Scleroderma, Systemic, Scleroderma, Diffuse, Rheumatoid Arthritis
Interventions
Custom Fabricated Splint
Other
Lead sponsor
Giovanna Fichera
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Troy, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Jul 22, 2026, 12:34 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Exparel as a Nerve Block for Severe Hand Pain

NCT02374320
View directory record Official record
Conditions
CREST Syndrome, Peripheral Vascular Disease, Raynaud Disease, Scleroderma, Diffuse
Interventions
liposomal bupivacaine
Drug
Lead sponsor
Jose Soberon, MD
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Jul 22, 2026, 12:34 PM EDT
Completed Phase 1 Interventional

Treatment of Palmar Plantar Erythrodysesthesia (PPE) With Topical Sildenafil

NCT01219023
View directory record Official record
Conditions
Hand Foot Syndrome, Palmar Plantar Erythrodysesthesia
Interventions
sildenafil citrate
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Jul 22, 2026, 12:34 PM EDT
Terminated Not applicable Interventional

A Study to Assess CLn® BodyWash for Reducing Skin Fauna in Patients With Hand Eczema

NCT01826630
View directory record Official record
Conditions
Eczema, Hand Eczema, Atopic Dermatitis
Interventions
CLn BodyWash, Cetaphil Daily Facial Cleanser
Other
Lead sponsor
Shari L Hand
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Gahanna, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Jul 22, 2026, 12:34 PM EDT
Completed Phase 3 Interventional

A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy

NCT05958407
View directory record Official record
Conditions
Atopic Dermatitis, Atopic Hand Eczema
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Jul 22, 2026, 12:34 PM EDT
Completed Not applicable Interventional Results available

CellFX System for the Treatment of Cutaneous Non-Genital Warts

NCT04554394
View directory record Official record
Conditions
Warts, Warts Hand, Verruca
Interventions
CellFX Device
Device
Lead sponsor
Pulse Biosciences, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Scottsdale, Arizona • San Diego, California • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jul 22, 2026, 12:34 PM EDT
Completed Phase 2 Interventional

A Study to Examine the Safety and Toleration of PEP005 Topical Gel in Patients With Actinic Keratoses on the Top of the Hand

NCT00544297
View directory record Official record
Conditions
Actinic Keratosis
Interventions
PEP005 gel
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
San Diego, California • Snellville, Georgia • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Jul 22, 2026, 12:34 PM EDT
Completed Phase 2 Interventional

DOXIL for Consolidation Therapy in Ovarian Cancer.

NCT00248248
View directory record Official record
Conditions
Ovarian Neoplasm
Interventions
liposomal doxorubicin
Drug
Lead sponsor
Southeastern Gynecologic Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 11, 2011 · Synced Jul 22, 2026, 12:34 PM EDT
Terminated Phase 3 Interventional Results available

Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer

NCT00305643
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Pain
Interventions
Capecitabine, Celecoxib, Radiation Therapy, Placebo
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
13
States / cities
Santa Rosa, California • Grand Rapids, Michigan • Kalamazoo, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Jul 22, 2026, 12:34 PM EDT
Completed Phase 2 Interventional

Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon

NCT00378521
View directory record Official record
Conditions
Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Autoimmune Disease
Interventions
MQX-503
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Timeline
2006
U.S. locations
1
States / cities
Renton, Washington
Source: ClinicalTrials.gov public record
Updated May 29, 2007 · Synced Jul 22, 2026, 12:34 PM EDT
Terminated Not applicable Interventional

Pulsed 1064nm Nd:YAG in the Treatment of Verruca Vulgaris Versus Conventional Therapy With Liquid Nitrogen Cryotherapy

NCT01609530
View directory record Official record
Conditions
Verruca Vulgaris
Interventions
Liquid Nitrogen Cryotherapy, Pulsed 1064nm Nd:YAG
Procedure
Lead sponsor
Trinity Health Michigan
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Ypsilanti, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Jul 22, 2026, 12:34 PM EDT
Completed Phase 4 Interventional Results available

Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.

NCT01323673
View directory record Official record
Conditions
Dermatitis, Chronic
Interventions
clobetasol propionate 0.05%, Vehicle / Placebo
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
10
States / cities
San Diego, California • Boynton Beach, Florida • West Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Jul 22, 2026, 12:34 PM EDT
Completed Not applicable Interventional Results available

CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts

NCT04738734
View directory record Official record
Conditions
Warts, Warts Hand, Verruca
Interventions
CellFX System Device, Cryosurgery Liquid Nitrogen Sprayer
Device
Lead sponsor
Pulse Biosciences, Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Scottsdale, Arizona • Beverly Hills, California • Greenwood Village, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced Jul 22, 2026, 12:34 PM EDT
Recruiting No phase listed Observational

Screening For BCRL In Targeted Therapy For Breast Cancer

NCT05142800
View directory record Official record
Conditions
Lymphedema, Lymphedema Arm, Lymphedema of Upper Arm, Lymphedema of Upper Limb, Lymphedema of the Hands, Edema, Edema Arm, Breast Cancer Lymphedema, Breast Cancer Metastatic, Breast Cancer Stage, Breast Cancer
Interventions
Perometer, SOZO device
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 22, 2026, 12:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

TCA 15% Chemical Peel for Improvement in Hand Lentigines

NCT05471947
View directory record Official record
Conditions
Photoaging, Lentigo
Interventions
15% Trichloroacetic acid + 3% glycolic acid
Drug
Lead sponsor
Main Line Center for Laser Surgery
Other
Eligibility
22 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Ardmore, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Jul 22, 2026, 12:34 PM EDT
Completed Phase 1 Interventional

Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.

NCT02748902
View directory record Official record
Conditions
Verruca Vulgaris, Common Warts
Interventions
ingenol mebutate 0.05% gel
Drug
Lead sponsor
Neal D. Bhatia, MD
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2017 · Synced Jul 22, 2026, 12:34 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands

NCT00973856
View directory record Official record
Conditions
Papillomavirus Infections, Warts, Condylomata Acuminata, Epidermodysplasia Verruciformis
Interventions
PURELL VF481, Placebo Solution
Other
Lead sponsor
Cleveland Clinic Akron General
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Jul 22, 2026, 12:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Single-Center 2-Arm Study for Lentigines on the Hands

NCT02763072
View directory record Official record
Conditions
Lentigines
Interventions
Enlighten Laser, Excel V Laser
Device
Lead sponsor
Cutera Inc.
Industry
Eligibility
30 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Naperville, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Jul 22, 2026, 12:34 PM EDT